Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma

BACKGROUND: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility and safety of cetuximab-based IC (paclitaxel/carboplatin/cetuximab—PCC, and doce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Haddad, R.I., Massarelli, E., Lee, J.J., Lin, H.Y., Hutcheson, K., Lewis, J., Garden, A.S., Blumenschein, G.R., William, W.N., Pharaon, R.R., Tishler, R.B., Glisson, B.S., Pickering, C., Gold, K.A., Johnson, F.M., Rabinowits, G., Ginsberg, L.E., Williams, M.D., Myers, J., Kies, M.S., Papadimitrakopoulou, V.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Head and neck tumor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360148/
https://ncbi.nlm.nih.gov/pubmed/30596812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados